New therapies in development for autoimmune diseases: their rationale for combination treatment

  • Vibeke Strand
General Section


  1. 1.
    Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al (1999) CTLA4Ig-mediated blockade of T cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103: 1243PubMedCrossRefGoogle Scholar
  2. 2.
    Alcocer-Varela J, Llorente L, Alarcon-Segovia D (1996) Immunoregulatory circuits and potential treatment of connective tissue diseases. Int Arch Allergy Immunol 111: 348PubMedCrossRefGoogle Scholar
  3. 3.
    Al-Janadi M, Al-Dalaan A, Al-Balla S, et al (1996) IL-10 secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10 dependent CD4+CD45RO T cell-B cell antibody synthesis. J Clin Immunol 16:198PubMedCrossRefGoogle Scholar
  4. 4.
    Apparailly F, Verwarde C, Jacquet C, et al (1998) Chondroprotective effect of gene transfer of IL-10 in type I collagen-induced arthritis. J Immunol 160: 5213PubMedGoogle Scholar
  5. 5.
    Badger A, Swift B, Rieman D, Stroup G, et al (1999) Effect of SB273005, an orally active, non-pep-tide avb3 vitronectin receptor antagonist in the adjuvant arthritic rat. Arthritis Rheum 42: s118Google Scholar
  6. 6.
    Barnes DA, Tse J, Kaufhold M, et al (1998) Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J Clin Invest 101: 2910PubMedCrossRefGoogle Scholar
  7. 7.
    Barnett ML, Kremer JM, St. Clair EW, et al (1998) Treatment of rheumatoid arthritis with oral type II collagen: Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 41: 290PubMedCrossRefGoogle Scholar
  8. 8.
    Bendele AM, Chlipala ES, Rich WR, Edwards CK (1999) Combination benefit of treatment with recombinant IL-Ira and pegylated recombinant human soluble TNF-R type I on animal models of rheumatoid arthritis. Arthritis Rheum 42: S171Google Scholar
  9. 9.
    Beutler B (1995) TNF, immunity and inflammatory disease: lessons of the past decade. J Invest Med 43:227Google Scholar
  10. 10.
    Burger D, Rezzonico R, Li J-M, Modoux C, et al (1998) Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes. Arthritis Rheum 41:1748PubMedCrossRefGoogle Scholar
  11. 11.
    Chuzhin Y, Reddy B, Budhai L, et al (1998) Prolonged survival in murine SLE by adenoviral mediated CTLA41g gene transfer. Arthritis Rheum 41: S140Google Scholar
  12. 12.
    Daikh DI, Finck BK, Linsley PS, et al (1997) Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 159:304Google Scholar
  13. 13.
    Davidson A, Budhai L, Reddy B, Viashnaw A, Furie R (2000) The effect of anti-CD40L on B cells in human SLE. Arthritis Rheum 43:S271Google Scholar
  14. 14.
    Davis JC, Totoritis MC, Sklenar TA, Wofsy D (1999) Results of a phase I single dose dose escalating trial of a humanized antiCD40L monoclonal antibody (IDEC 131) in patients with SLE. Arthritis Rheum 42:S281Google Scholar
  15. 15.
    Davis L, Kavanaugh AF, Nichols LA, Lipsky P (1995) Induction of persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis. J Immunol 154: 3525PubMedGoogle Scholar
  16. 16.
    De Waal Malefijt R, Chromarat P, Vannier E, et al (1995) Balance of IL-1 receptor antagonist/IL-lB in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 154: 1432Google Scholar
  17. 17.
    Dinarello CA, Wolff SM (1993) The role of interleukin-1 in disease. N Engl J Med 328:106PubMedCrossRefGoogle Scholar
  18. 18.
    Evans C, Ghivizzani SC, Kang R, Muzzonigro, et al. (1999) Gene therapy for rheumatic diseases. Arthritis Rheum 42: 1PubMedCrossRefGoogle Scholar
  19. 19.
    Feige U, Campagnuolo G, Cheng Y, Bolon B (1999) Osteoprotegerin decreases bone resorption in adjuvant arthritis in Lewis rats. Arthritis Rheum 42:S120Google Scholar
  20. 20.
    Feige U, Hu YL, Julian E, Duryea D, Bolon B (1999) Combining anti-IL-1 and anti-TNF treatments provides better efficacy in rat adjuvant arthritis than does either agent alone. Arthritis Rheum 42:S383Google Scholar
  21. 21.
    Finck BK, Linsley PS, Wofsy D (1994) Treatment of murine lupus with CTLA41g. Science 265:1225PubMedCrossRefGoogle Scholar
  22. 22.
    Firestein GS, Escheverri F, Yeo M, et al (1996) Somatic mutations in the P53 tumor suppressor gene in rheumatoid arthritis (RA) synovium. J Clin Invest 96: 1631CrossRefGoogle Scholar
  23. 23.
    Foy TM, Aruffo A, Bajorath J, Buhlmanin JE, Noelle RJ (1996) Immune regulation by CD40 and its ligand of p39. Annu Rev Immunol 14: 591PubMedCrossRefGoogle Scholar
  24. 24.
    Fujisawa K, Asahara H, Okamoto K, et al (1996) Therapeutic effects of the anti-Fas antibody on arthritis in the HTLV-l tax transgenic mice. J Clin Invest 98: 271PubMedCrossRefGoogle Scholar
  25. 25.
    Gaur A, Fathman CG (1994) Immunotherapeutic strategies directed at the trimolecular complex. Adv Immunol 56:219PubMedCrossRefGoogle Scholar
  26. 26.
    Gerlag DM, Bprges E, Ellerby HM, et al (1999) Targeted apoptosis of synovial neovasculature in murine collagen induced arthritis. Arthritis Rheum 42:S120Google Scholar
  27. 27.
    Ghivizzani SC (1998) Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sei USA 95:4613CrossRefGoogle Scholar
  28. 28.
    Gong JH, Ratkey LG, Waterfield JD, et al (1997) An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-Lpr mouse model. J Exp Med 186:131PubMedCrossRefGoogle Scholar
  29. 29.
    Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, et al (1999) A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 104:1393PubMedCrossRefGoogle Scholar
  30. 30.
    Grammer AC, Bergman MC, Miura Y, et al (1995) The CD40 ligand expressed by human B cells co-stimulates B cell responses. J Immunol 154:4996PubMedGoogle Scholar
  31. 31.
    Grewal IS, Flavell RA (1996) A central role of CD40 ligand in the regulation of CD4-T cell responses. Immunol Today 17: 410PubMedCrossRefGoogle Scholar
  32. 32.
    Grondal G, Kristjansdottir H, Traustadottir KH, et al (1998) IL-10 production and apoptosis in SLE patients and their spouses in icelandic SLE-multicase families. Arthritis Rheum 41: S283Google Scholar
  33. 33.
    Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, et al (1999) Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 340:1704PubMedCrossRefGoogle Scholar
  34. 34.
    Haqqi TM, Qu X-M, Anthony D, Ma J, Sy M-S (1996) Immunization with T cell receptor Vb chain peptides deletes pathogenic T cells and prevents the induction of collagen-induced arthritis in mice. J Clin Invest 334:395Google Scholar
  35. 35.
    Hermann JA, Hall MA, Maini RN, Feldmann M, Brennan FM (1998) Important immunoregulatory role of IL-11 in the inflammatory process in RA. Arthritis Rheum 41:1388PubMedCrossRefGoogle Scholar
  36. 36.
    Iigo Y, Takashi T, Tamatani T, et al (1991) ICAM-1 dependent pathway is critically involved in the pathogenesis of adjuvant arthritis in rats. J Immunol 147:4167PubMedGoogle Scholar
  37. 37.
    Ishida H, Muchamuel T, Sakaguchi S, et al (1994) Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W Fl mice. J Exp Med 179:305PubMedCrossRefGoogle Scholar
  38. 38.
    Jasen HE, Lightfoot E, Davis LS, et al (1992) Amelioration of antigen-induced arthritis in rabbits treated with monoclonal antibodies to leukocyte adhesion molecules. Arthritis Rheum 35:541CrossRefGoogle Scholar
  39. 39.
    Joosten LAB, Lubberts E, Durez P, et al (1997) Role of IL-4 and IL-10 in murine collagen induced arthritis: protective effect of IL-4 and IL-10 treatment on cartilage destruction. Arthritis Rheum 40:249PubMedCrossRefGoogle Scholar
  40. 40.
    Kakimoto K, Nakamura T, Ishii K, et al (1992) The effect of anti-adhesion molecule antibody on the development of collagen-induced arthritis. Cell Immunol 142:326PubMedCrossRefGoogle Scholar
  41. 41.
    Kalden JR, Sieper J (1998) Oral collagen in the treatment of rheumatoid arthritis. Arthritis Rheum 41:191PubMedCrossRefGoogle Scholar
  42. 42.
    Kalled SL, Cutler AH, Datta SK, Thomas DW (1998) Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 160:2158PubMedGoogle Scholar
  43. 43.
    Kalunian K, Davis J, Merrill JT, et al (2000) Treatment of SLE by inhibition of T cell costimulation. Arthritis Rheum 43: S271Google Scholar
  44. 44.
    Kanakami A, Eguchi K, Matsuoka N, et al (1997) Inhibitory effects of interleukin-10 in rheumatoid arthritis. Immunology 91: 252CrossRefGoogle Scholar
  45. 45.
    Kasama T, Strieter RM, Lukacs NW, et al (1995) Interleukin 10 expression and chemokine regulation during the evolution of murine type II collagen induced arthritis. J Clin Invest 95:2868PubMedCrossRefGoogle Scholar
  46. 46.
    Kavanaugh A, Davis LS, Jain R, et al (1996) A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody therapy in early rheumatoid arthritis. J RheumatolGoogle Scholar
  47. 47.
    Kavanaugh AF, Davis LS, Nichols LA, et al (1994) Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule-1. Arthritis Rheum 37:992PubMedCrossRefGoogle Scholar
  48. 48.
    Koch AE (1998) Angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 41:951PubMedCrossRefGoogle Scholar
  49. 49.
    Kohno K, Kurimoto M (1998) IL-18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both. Clin Immunol Immunopathol 86: 11PubMedCrossRefGoogle Scholar
  50. 50.
    Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell co-stimulation. Annu Rev Immunol 14: 233PubMedCrossRefGoogle Scholar
  51. 51.
    Llorente L, Richaud-Patin Y, Garcia-Padilla C, et al (2000) Clinical and biological effects of anti-in-terleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43:1790PubMedCrossRefGoogle Scholar
  52. 52.
    Llorente L, Zou W, Lewy Y, et al (1995) Role of interleukin-10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181:839PubMedCrossRefGoogle Scholar
  53. 53.
    Lockwood CM, Elliott JD, Brettman L, Hale G, Rebello P, Frewin M, Ringler D, Merril C, Waldmann H, Clin Immunol 93:93Google Scholar
  54. 54.
    Lubberts E, Joosten LAB, Bersselaar L van den, et al (1999) Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen induced arthritis prevents cartilage destruction. J Immunol 163:4546PubMedGoogle Scholar
  55. 55.
    Ma Y, Duwel L, Thornton S, et al (1997) Viral IL-10 gene therapy inhibits collagen-induced arthritis in mice. Arthritis Rheum 40: S158Google Scholar
  56. 56.
    Maini RN, Paulus H, Breedveld PC, et al (1997) HuIL-10 in subjects with active rheumatoid arthritis (RA): a phase I and cytokine response study. Arthritis Rheum 40: S224Google Scholar
  57. 57.
    Maksymowych W, Blackburn W, Hutchings E, Williams L, Tami J, Wagner K Shanahan W (1999) A pilot study of ISIS 2302: an antisense nucleotide in patients with active RA. Arthritis Rheum 42: S170Google Scholar
  58. 58.
    Malfait AM, et al (1998) Blockade of IL-12 during the induction of collagen-induced arthritis markedly attenuates the severity of the arthritis. Clin Exp Immunol 111: 377PubMedCrossRefGoogle Scholar
  59. 59.
    Matis LA, Rollins SA (1995) Complement-specific antibodies: designing novel anti-inflammatories. Nat Med 1:839PubMedCrossRefGoogle Scholar
  60. 60.
    Matsumoto AK, Moreland LW for the. Study Group, Strand V, Morgan EE, Nardo CJ, Richieri SP, Brostoff SW (1999) Results of a phase IIB rheumatoid arthritis clinical trial using T cell receptor peptides. Arthritis Rheum 42:S117Google Scholar
  61. 61.
    Mauri C, Williams RO, Walmsley M, Feldmann M (1996) Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 26:1511PubMedCrossRefGoogle Scholar
  62. 62.
    McKown KM, Carbone LD, Bustillo J, Seyer JM, et al (2000) Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum 43:1054PubMedCrossRefGoogle Scholar
  63. 63.
    Merino J, Revilla C, Conde C, et al (1994) The effects of the treatment with anti-LFA-la or anti-ICAM-1 mAb on the tolerance and autoimmunity in mice injected at birth with Fl hybrid cells depends on the saturation of these molecules in different lymphoid organs. Arthritis Rheum 37:S390Google Scholar
  64. 64.
    Milkacz K, Brennan FR, Kim JH, et al (1994) Immunotherapy with antibodies to cell adhesion molecules in proteoglycan-induced arthritis. Arthritis Rheum 37:S397Google Scholar
  65. 65.
    Miotla JM, Paleolog E, Maciewicz R, Kendrew J, et al (1999) Blockade of vascular endothelial growth factor activity attenuates murine collagen-induced arthritis. Arthritis Rheum 42:S121Google Scholar
  66. 66.
    Mohan C, Shi Y, Laman JD, Datta SK (1995) Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 154:1470PubMedGoogle Scholar
  67. 67.
    Mojcik CF, Shevach EM. (1997) Adhesion molecules: a rheumatologic perspective. Arthritis Rheum 40:991PubMedCrossRefGoogle Scholar
  68. 68.
    Moreland LW, Morgan EE, Adamson TC III, Calabrese LH, et al (1998) T cell receptor peptide vaccination in rheumatoid arthritis: a placebo controlled trial using a combination of Vb3, 14 and 17 peptides. Arthritis Rheum 41:1919PubMedCrossRefGoogle Scholar
  69. 69.
    Morita Y, et al (1998) Expression of IL-12 in synovial tissue from patients with RA. Arthritis Rheum 41:306PubMedCrossRefGoogle Scholar
  70. 70.
    Mosmann TR, Sad S (1996) The expanding universe of T cell subsets: TH1, Th2 and more. Immunol Today 17:13CrossRefGoogle Scholar
  71. 71.
    Muller-Ladner U, Franklin B, Roberts C et al (1996) Gene transfer for IL-10 into human synovial fibroblasts and implantation into the SCID mouse. Arthritis Rheum 39: SI60Google Scholar
  72. 72.
    Nagler-Anderson C, Bober LA, Robinson ME, et al (1986) Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sei USA 83:7443CrossRefGoogle Scholar
  73. 73.
    Nakajima T, Hono H, Hasunuma T, et al (1995) Apoptosis and functional fas antigen in RA synoviocytes. Arthritis Rheum 38: 485PubMedCrossRefGoogle Scholar
  74. 74.
    Neurath MF, et al (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182:1281PubMedCrossRefGoogle Scholar
  75. 75.
    Oliver SJ, Cheng TP, Banquerigo ML, Brahn E (1995) Suppression of collagen induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin. Cell Immunol 166: 196PubMedCrossRefGoogle Scholar
  76. 76.
    Paliard X, West SG, Lafferty J, et al (1991) Evidence for the effects of a superantigen in rheumatoid arthritis. Science 253:325PubMedCrossRefGoogle Scholar
  77. 77.
    Park Y, Lee SK, Kim DS, et al (1998) Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 16:283PubMedGoogle Scholar
  78. 78.
    Plater-Zyberk C, Hoogewerf AJ, Proudfoot AE, et al (1997) Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett 57:117PubMedCrossRefGoogle Scholar
  79. 79.
    Pourie F, Menon S, Coffman RL (1993) Interleukin 4 and interleukin 10 are synergistic to inhibit cell-mediated immunity in vivo. Eur J Immunol 23:2223CrossRefGoogle Scholar
  80. 80.
    Prasad NKA, Papoff G, Zeuner A, et al (1998) Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the fas apoptotic pathway. J Immunol 161:3781PubMedGoogle Scholar
  81. 81.
    Probert L, Plows D, Kontogeorgos G, Kollias G (1995) The type I IL-1 receptor acts in series with TNF-α to induce arthritis in TNF-α transgenic mice. Eur J Immunol 25:1794PubMedCrossRefGoogle Scholar
  82. 82.
    Racke MK, Bonomo A, Scott DE, et al (1994) Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 180:1961PubMedCrossRefGoogle Scholar
  83. 83.
    Raz E, Dudler J, Lotz M, et al (1995) Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 4:286PubMedCrossRefGoogle Scholar
  84. 84.
    Reiser H, Stadecker MJ (1996) Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 335:1369PubMedCrossRefGoogle Scholar
  85. 85.
    Rönnelid J, Nillson B (1998) Immune complexes from SLE sera induce IL-10 production. A possible vicious circle maintaining B cell hyperactivity in SLE. Arthritis Rheum 41:S67Google Scholar
  86. 86.
    Ruchatz H, Leung BP, Wei X-Q, McInnes IB, Liew FY (1998) Soluble IL-15 receptor alpha chain administration prevents murine collagen induced arthritis: a role for IL-15 in development of antigen induced immunopathology. J Immunol 160:5654PubMedGoogle Scholar
  87. 87.
    Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS (1995) Elevated TH1- or THO-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis, modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol 155:5029PubMedGoogle Scholar
  88. 88.
    Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS (1996) Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis responding to treatment with a monoclonal antibody to CD54 (ICAM-1). Clin Exp Immunol 106:190PubMedCrossRefGoogle Scholar
  89. 89.
    Souza D, Raymond E, Nabozny G, Ridgefiled CT (1999) Synergistic inhibition of collagen induced arthritis through dual inhibition of ICAM-1 and CD40L pathways. Arthritis Rheum 42: S124Google Scholar
  90. 90.
    St Clair EW, Cohen SB, Lee ML, Fleischmann RM, et al (2000) Treatment of rheumatoid arthritis with a DR4/1 peptide. J Rheumatol 27:1855PubMedGoogle Scholar
  91. 91.
    Strand V (1996) The future use of biological agents in combination for treatment of rheumatoid arthritis. J Rheumatol 23: 91Google Scholar
  92. 92.
    Struyk L, Hawes GE, Chatila MK, et al (1995) T cell receptors in rheumatoid arthritis. Arthritis Rheum 38:577PubMedCrossRefGoogle Scholar
  93. 93.
    Szekanecz Z, Strieter RM, Kunkel SL, Koch AE (1998) Chemokines in rheumatoid arthritis. Springer Semin Immunopathol 20:115PubMedCrossRefGoogle Scholar
  94. 94.
    Trinchieri G (1998) Proinflammatory and immunoregulatory functions of IL-12. Int Rev Immunol 16:365PubMedCrossRefGoogle Scholar
  95. 95.
    Van Roon JAG, Roy JLAM van, Gmelig-Meyling FHJ, et al (1996) Prevention and reversal of cartilage degradation in rheumatoid arthritis by IL-10 and IL-4. Arthritis Rheum 39: 829PubMedCrossRefGoogle Scholar
  96. 96.
    Wang D, Reddy B, Mihara M, et al (2000) Mechanism of action of short term combination of CTLA4Ig/CD40L therapy in murine SLE. Arthitis Rheum 43:S92Google Scholar
  97. 97.
    Wang Y, Hu Q, Madre JA, et al (1996) Amelioration of lupus-like autoimmune disease in NZB/W Fl mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sei USA 93:8563CrossRefGoogle Scholar
  98. 98.
    Wang Y, Hu O, Kristan J et al (1996) Subcutaneous administration of anti-C5 monoclonal antibody induces systemic complement inhibition and ameliorates immune complex mediated inflammatory responses. Arthritis Rheum 39:S245Google Scholar
  99. 99.
    Whalen J, Carlos CA, Robbins P, et al (1997) Periarticular gene therapy with viral IL-10 can prevent collagen-induced arthritis in mice. Arthritis Rheum 40: S158Google Scholar
  100. 100.
    Williams RO, Feldmann M, Maini RN (1992) Anti-TNF meliorates joint disease in murine collagen induced arthritis. Proc Natl Acad Sei USA 89:9784CrossRefGoogle Scholar
  101. 101.
    Wooley PH, Luthra HS, Lafuse WP, e al (1985) Type II collagen-induced arthritis in mice. III. Suppression of arthritis by using monoclonal and polyclonal anti-la antisera. Immunology 134:2366Google Scholar
  102. 102.
    Yachyshyn BR, Bowen-Yacashyn MG, Jewell L, et al (1998) A placebo controlled trial of ICAM-1 antisense oligoneucleotide in the treatment of Crohn’s disease. Gastroenterology 114:1133CrossRefGoogle Scholar
  103. 103.
    Yellin MJ, D’Agati V, Parkinson G, et al (1997) Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 40:124PubMedCrossRefGoogle Scholar
  104. 104.
    Zang ZJ, Lee CS, Lider O, et al (1990) Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J Immunol 145:2489Google Scholar
  105. 105.
    Zhang H, Yang Y, Horton JL, et al (1997) Amelioration of collagen-induced arthritis by CD95 (Apo-l/Fas)-ligand expressing APCs as a therapy of autoimmune disease. J Clin Invest 100: 1951PubMedCrossRefGoogle Scholar
  106. 106.
    Zuniga-Pflucker JC, Jiang D, Leonardo MJ (1995) Requirement for TNF-α and IL-1α in fetal thymocyte commitment and differentiation. Science 268: 1906PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2001

Authors and Affiliations

  • Vibeke Strand
    • 1
  1. 1.Clinical Faculty (VCF), Division of ImmunologyStanford University School of MedicinePortola ValleyUSA

Personalised recommendations